
Opinion|Videos|September 11, 2024
Understanding Oligometastatic Disease in Prostate Cancer: Insights from PSMA PET Imaging
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do imaging agents, such as PSMA PET or other radiotracers, contribute to the detection and characterization of oligometastasis in prostate cancer patients?
Advertisement
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What New Phase 3 MRI Findings Reveal About Survodutide in Patients with Obesity and MASLD
2
Mammography Study: Can AI Detect Potential Breast Cancer Up to a Decade Prior to Diagnosis?
3
PSMA PET Plays Key Role in Multinational Phase 3 Trial of Perioperative Apalutamide for PCa
4
The 2026 Medicare shift in radiology: What changes, what to do
5












